UBS’s Crescent Biopharma CBIO Stock Holding History

UBS’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-6	Closed	-$11K	–	10559
2014 Q1	$11K	Buy	+6	New	+$7.26K	﹤0.01%	8793

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSA

Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS's CBIO Position: Q2 2014 in Review

UBS sold out of Crescent Biopharma (CBIO) in Q2 2014, closing a stake of 6 shares — an estimated $11K sold.

UBS first reported a position in CBIO in Q1 2014 and held it in 1 quarter. The position peaked at $11K in Q1 2014. 32 funds tracked by Wall St. Rank hold CBIO as of Q2 2014.

UBS reported no remaining Crescent Biopharma position as of Q2 2014 after selling out during the quarter.
UBS sold 6 Crescent Biopharma shares in Q2 2014, an estimated $11K.
UBS first reported a position in Crescent Biopharma in Q1 2014 and held it in 1 quarter.
UBS's Crescent Biopharma position peaked at $11K in Q1 2014.
32 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.